{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:20:10Z","timestamp":1787800810553,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01409-w","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:09:28Z","timestamp":1787800168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Treatment Options Guided by Molecular Classification in Endometrial Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Qingyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-3481","authenticated-orcid":false,"given":"Zhengmao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"3","key":"1409_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1409_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41571-024-00934-7","volume":"21","author":"JA How","year":"2024","unstructured":"How JA, Jazaeri AA, Westin SN, et al. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024;21(11):781\u2013800. https:\/\/doi.org\/10.1038\/s41571-024-00934-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1409_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2108330.","journal-title":"N Engl J Med"},{"issue":"2","key":"1409_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","volume":"113","author":"A Talhouk","year":"2015","unstructured":"Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299\u2013310. https:\/\/doi.org\/10.1038\/bjc.2015.190.","journal-title":"Br J Cancer"},{"issue":"7447","key":"1409_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373. https:\/\/doi.org\/10.1038\/nature12113.","journal-title":"Nature"},{"issue":"1","key":"1409_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","volume":"143","author":"A Talhouk","year":"2016","unstructured":"Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol. 2016;143(1):46\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.090.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1409_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383\u201394. https:\/\/doi.org\/10.1002\/ijgo.14923.","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"1409_CR8","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","volume":"38","author":"M K\u00f6bel","year":"2019","unstructured":"K\u00f6bel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol. 2019;38(Suppl 1):S123\u201331. https:\/\/doi.org\/10.1097\/PGP.0000000000000488.","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"1409_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.5372","volume":"250","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, Britton H, McConechy MK, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol. 2020;250(3):323\u201335. https:\/\/doi.org\/10.1002\/path.5372.","journal-title":"J Pathol"},{"key":"1409_CR10","doi-asserted-by":"publisher","unstructured":"Martin SD, McAlpine JN. Key considerations for safe de-escalation of therapy for POLE mutated endometrial cancer. Int J Gynecol Cancer Published online March. 2026;2. https:\/\/doi.org\/10.1016\/j.ijgc.2025.102810.","DOI":"10.1016\/j.ijgc.2025.102810"},{"issue":"29","key":"1409_CR11","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","volume":"38","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388\u201397. https:\/\/doi.org\/10.1200\/JCO.20.00549.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1409_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/ijgc-2022-003676","volume":"33","author":"H Karpel","year":"2023","unstructured":"Karpel H, Slomovitz B, Coleman RL, Pothuri B. Biomarker-driven therapy in endometrial cancer. Int J Gynecol Cancer. 2023;33(3):343\u201350. https:\/\/doi.org\/10.1136\/ijgc-2022-003676. Published 2023 Mar 6.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1409_CR13","doi-asserted-by":"publisher","first-page":"hoac057","DOI":"10.1093\/hropen\/hoac057","volume":"2023","author":"A Rodolakis","year":"2023","unstructured":"Rodolakis A, Scambia G, Planchamp F, et al. ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023;2023(1):hoac057. https:\/\/doi.org\/10.1093\/hropen\/hoac057. Published 2023 Feb 6.","journal-title":"Hum Reprod Open"},{"issue":"7","key":"1409_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","volume":"40","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752\u201361. https:\/\/doi.org\/10.1200\/JCO.21.01874.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1409_CR15","doi-asserted-by":"publisher","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. https:\/\/doi.org\/10.1136\/jitc-2021-003777.","journal-title":"J Immunother Cancer"},{"issue":"23","key":"1409_CR16","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2302312.","journal-title":"N Engl J Med"},{"issue":"5","key":"1409_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","volume":"31","author":"RN Eskander","year":"2025","unstructured":"Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025;31(5):1539\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03566-1.","journal-title":"Nat Med"},{"issue":"23","key":"1409_CR18","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2216334.","journal-title":"N Engl J Med"},{"issue":"8","key":"1409_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","volume":"35","author":"MA Powell","year":"2024","unstructured":"Powell MA, Bj\u00f8rge L, Willmott L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial. Ann Oncol. 2024;35(8):728\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.546.","journal-title":"Ann Oncol"},{"issue":"14","key":"1409_CR20","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/cncr.33516","volume":"127","author":"JN McAlpine","year":"2021","unstructured":"McAlpine JN, Chiu DS, Nout RA, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer. 2021;127(14):2409\u201322. https:\/\/doi.org\/10.1002\/cncr.33516.","journal-title":"Cancer"},{"issue":"20","key":"1409_CR21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol. 2018;36(20):2044\u201351. https:\/\/doi.org\/10.1200\/JCO.2017.76.5966.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1409_CR22","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0953.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1409_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1409_CR24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.20.03167","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu JF, Xiong N, Campos SM, et al. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 2021;39(14):1531\u20139. https:\/\/doi.org\/10.1200\/JCO.20.03167.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1409_CR25","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO-24-01606","volume":"43","author":"JF Liu","year":"2025","unstructured":"Liu JF, Colombo N, Oza AM, et al. ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. J Clin Oncol. 2025;43(26):2897\u2013907. https:\/\/doi.org\/10.1200\/JCO-24-01606.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1409_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024;42(3):283\u201399. https:\/\/doi.org\/10.1200\/JCO.23.02132.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1409_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","volume":"33","author":"RAINBO Research Consortium","year":"2023","unstructured":"RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer. 2023;33(1):109\u201317. https:\/\/doi.org\/10.1136\/ijgc-2022-004039. Published 2023 Jan 3.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"1409_CR28","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/cancers15061799","volume":"15","author":"VM Wagner","year":"2023","unstructured":"Wagner VM, Backes FJ. Do not forget about hormonal therapy for recurrent endometrial cancer: a review of options, updates, and new combinations. Cancers (Basel). 2023;15(6):1799. https:\/\/doi.org\/10.3390\/cancers15061799. Published 2023 Mar 16.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1409_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.22.00628","volume":"41","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Lee EK, Xiong N, et al. A Phase II, Two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer. J Clin Oncol. 2023;41(3):599\u2013608. https:\/\/doi.org\/10.1200\/JCO.22.00628.","journal-title":"J Clin Oncol"},{"key":"1409_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","volume":"192","author":"MR Mirza","year":"2025","unstructured":"Mirza MR, Bj\u00f8rge L, Marm\u00e9 F, et al. Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial. Gynecol Oncol. 2025;192:128\u201336. https:\/\/doi.org\/10.1016\/j.ygyno.2024.12.003.","journal-title":"Gynecol Oncol"},{"issue":"35","key":"1409_CR31","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1200\/JCO.22.02906","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, P\u00e9rez-Fidalgo JA, Hamilton EP, et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J Clin Oncol. 2023;41(35):5400\u201310. https:\/\/doi.org\/10.1200\/JCO.22.02906.","journal-title":"J Clin Oncol"},{"key":"1409_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ygyno.2024.05.016","volume":"185","author":"V Makker","year":"2024","unstructured":"Makker V, Perez-Fidalgo JA, Valabrega G, et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5\/GOG-3055\/SIENDO study. Gynecol Oncol. 2024;185:202\u201311. https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.016.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1409_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(25)00612-6","volume":"27","author":"ASVM van den Heerik","year":"2026","unstructured":"van den Heerik ASVM, Horeweg N, Haverkort MAD, et al. Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial. Lancet Oncol. 2026;27(1):23\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(25)00612-6.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1409_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","volume":"25","author":"N Colombo","year":"2024","unstructured":"Colombo N, Biagioli E, Harano K, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(9):1135\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(24)00334-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1409_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","volume":"35","author":"T Van Gorp","year":"2024","unstructured":"Van Gorp T, Cibula D, Lv W, et al. ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024;35(11):968\u201380. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2242.","journal-title":"Ann Oncol"},{"issue":"6","key":"1409_CR36","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/ijgc-2020-002256","volume":"31","author":"A Jamieson","year":"2021","unstructured":"Jamieson A, Thompson EF, Huvila J, Gilks CB, McAlpine JN. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. Int J Gynecol Cancer. 2021;31(6):907\u201313. https:\/\/doi.org\/10.1136\/ijgc-2020-002256.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"1409_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/PGP.0000000000001012","volume":"43","author":"E Vaziri Fard","year":"2024","unstructured":"Vaziri Fard E, Imboden S, Rau T, et al. p53 Abnormal (copy number high) endometrioid endometrial carcinoma has a prognosis indistinguishable from serous carcinoma. Int J Gynecol Pathol. 2024;43(5):515\u201326. https:\/\/doi.org\/10.1097\/PGP.0000000000001012.","journal-title":"Int J Gynecol Pathol"},{"key":"1409_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ygyno.2025.02.005","volume":"194","author":"A Cort\u00e9s-Salgado","year":"2025","unstructured":"Cort\u00e9s-Salgado A, Moreno-Moreno E, Carretero-Barrio I, et al. HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study. Gynecol Oncol. 2025;194:33\u201340. https:\/\/doi.org\/10.1016\/j.ygyno.2025.02.005.","journal-title":"Gynecol Oncol"},{"key":"1409_CR39","doi-asserted-by":"publisher","first-page":"115329","DOI":"10.1016\/j.ejca.2025.115329","volume":"220","author":"G Villacampa","year":"2025","unstructured":"Villacampa G, Eminowicz G, Navarro V, et al. Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis. Eur J Cancer. 2025;220:115329. https:\/\/doi.org\/10.1016\/j.ejca.2025.115329.","journal-title":"Eur J Cancer"},{"key":"1409_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ygyno.2025.05.001","volume":"197","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Pang J, Zhou Y, et al. FR\u03b1 expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates. Gynecol Oncol. 2025;197:146\u201354. https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.001.","journal-title":"Gynecol Oncol"},{"key":"1409_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ygyno.2025.07.020","volume":"200","author":"M Marchetti","year":"2025","unstructured":"Marchetti M, Vezzaro T, Carollo M, et al. The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer. Gynecol Oncol. 2025;200:145\u201354. https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.020.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1409_CR42","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","volume":"26","author":"N Concin","year":"2025","unstructured":"Concin N, Matias-Guiu X, Cibula D, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(25)00167-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1409_CR43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ajog.2025.09.041","volume":"234","author":"F Ferrari","year":"2026","unstructured":"Ferrari F, Gozzini E, Torroni L, et al. Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2026;234(3):584\u2013605. https:\/\/doi.org\/10.1016\/j.ajog.2025.09.041.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"1409_CR44","doi-asserted-by":"publisher","first-page":"105755","DOI":"10.1016\/j.esmoop.2025.105755","volume":"10","author":"L Mastrantoni","year":"2025","unstructured":"Mastrantoni L, Camarda F, Parrillo C, et al. Gene actionability according to the ESMO Scale for clinical actionability of molecular targets (ESCAT) in no specific molecular profile (NSMP) endometrial cancer. ESMO Open. 2025;10(9):105755. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105755.","journal-title":"ESMO Open"},{"key":"1409_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ygyno.2024.02.020","volume":"185","author":"N Agusti","year":"2024","unstructured":"Agusti N, Kanbergs A, Nitecki R. Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer. Gynecol Oncol. 2024;185:121\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2024.02.020.","journal-title":"Gynecol Oncol"},{"key":"1409_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejogrb.2024.09.006","volume":"302","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhang X, Peng P, Yang J. Fertility-sparing treatment in MSI-H\/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2024;302:177\u201383. https:\/\/doi.org\/10.1016\/j.ejogrb.2024.09.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"1409_CR47","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ygyno.2021.03.029","volume":"161","author":"A Raffone","year":"2021","unstructured":"Raffone A, Catena U, Travaglino A, et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study. Gynecol Oncol. 2021;161(3):795\u2013801. https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.029.","journal-title":"Gynecol Oncol"},{"key":"1409_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ygyno.2024.04.013","volume":"186","author":"H Peng","year":"2024","unstructured":"Peng H, Jiang J, Li L, et al. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment. Gynecol Oncol. 2024;186:154\u201360. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.013.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1409_CR49","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.3802\/jgo.2025.36.e101","volume":"36","author":"Z Zhai","year":"2025","unstructured":"Zhai Z, Wang Y, Li H, Kang N, Liu Y, Wang J. Analysis of fertility-preserving treatment outcomes in patients with POLE-mutated endometrioid carcinoma. J Gynecol Oncol. 2025;36(4):e101. https:\/\/doi.org\/10.3802\/jgo.2025.36.e101.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"1409_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.17305\/bb.2025.12445","volume":"26","author":"J Wang","year":"2025","unstructured":"Wang J, Jiang G, Yan S, et al. Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia. Biomol Biomed. 2025;26(3):471\u201382. https:\/\/doi.org\/10.17305\/bb.2025.12445. Published 2025 Aug 31.","journal-title":"Biomol Biomed"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01409-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01409-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01409-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:09:31Z","timestamp":1787800171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01409-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01409-w","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"3 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Patient Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"44"}}